As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

The U.S. drugmaker spent nearly $2 billion in 2023 to acquire Versanis Bio's bimagrumab, which prevents the activity of a ...